Blurbs

Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Siemens Healthineers AG (SEMHFResearch Report) and Lineage Cell Therapeutics (LCTXResearch Report) with bullish sentiments.

Siemens Healthineers AG (SEMHF)

UBS analyst Graham Doyle maintained a Buy rating on Siemens Healthineers AG today and set a price target of EUR59.00. The company’s shares closed last Friday at $52.76.

Doyle has an average return of 8.2% when recommending Siemens Healthineers AG.

According to TipRanks.com, Doyle is ranked #7155 out of 8141 analysts.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Siemens Healthineers AG with a $59.26 average price target, which is a 12.3% upside from current levels. In a report issued on November 22, Barclays also maintained a Buy rating on the stock with a EUR64.00 price target.

See today’s best-performing stocks on TipRanks >>

Lineage Cell Therapeutics (LCTX)

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Lineage Cell Therapeutics today and set a price target of $7.00. The company’s shares closed last Friday at $1.42.

According to TipRanks.com, Pantginis has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -17.2% and a 32.7% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Genenta Science SpA Sponsored ADR, Bioline RX Ltd Sponsored ADR, and Applied Genetic Technologies.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Lineage Cell Therapeutics with a $5.40 average price target, a 267.3% upside from current levels. In a report issued on November 14, Robert W. Baird also maintained a Buy rating on the stock with a $5.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on SEMHF:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More